Angle Closure (Glaucoma) in Caucasians

Sponsor
Maastricht University Medical Center (Other)
Overall Status
Unknown status
CT.gov ID
NCT02054403
Collaborator
(none)
100
1
18
5.6

Study Details

Study Description

Brief Summary

Rationale: Primary angle closure glaucoma (PACG) causes high rates of blindness, either by means of a painful attack of acute angle closure glaucoma or unnoticed over a period of many years. Patients with angle closure are particularly at risk but can be detected during an ophthalmological examination and sent for early preventive (laser) intervention. Current practice shows that patients at risk of PACG are frequently missed during routine examinations. Moreover, new imaging techniques like swept source optical coherence tomography (SS-OCT), are emerging with which the angle of the anterior chamber can be imaged in great detail with no burden for the patient. These techniques are already used in clinical practice and replace and complete part of the ophthalmic examination. However, in Caucasians, it is not yet known to what extent angle closure is detected in regular care and can be detected with this OCT device. There are few published data concerning angle closure and PACG in Caucasians and its characteristics.

Objective: To quantify the presence of angle closure by gonioscopy in patients at risk of angle closure on SS-OCT. Secondary objectives are to quantify the presence of an increased intra-ocular pressure during the day or after dark provocation, to quantify morphometric details of the anterior chamber, structural changes, and corneal endothelial cells and to quantify the functional changes of the visual field.

Study design: prospective, observational, descriptive study. Study population: Caucasian patients, presenting at the outpatient clinic of the University Eye Clinic Maastricht, aged 40 to 80 years, who are diagnosed with angle closure on SS-OCT.

Intervention (if applicable): Not applicable. Main study parameters/endpoints: The main study parameter is assessment of the anterior chamber angle according to gonioscopy. Secondary study parameters are the presence of an increased intra-ocular pressure (IOP) (>21 mmHg) during the day or after dark provocation (IOP rise from baseline), morphometric details of the anterior chamber, structural changes of the retinal nerve fiber layer, number of corneal endothelial cells and functional changes of the visual field Hypothesis: It is hypothesised that, based on its resolution and ease of use, SS-OCT is a suitable imaging technique to identify patients with or at risk of angle closure. It will be of value as an additional diagnostic instrument and may even replace gonioscopy.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    100 participants
    Observational Model:
    Cohort
    Time Perspective:
    Cross-Sectional
    Official Title:
    Structural and Functional Parameters in Caucasian Patients With Angle Closure on SS-OCT
    Study Start Date :
    Apr 1, 2014
    Anticipated Primary Completion Date :
    Apr 1, 2015
    Anticipated Study Completion Date :
    Oct 1, 2015

    Arms and Interventions

    Arm Intervention/Treatment
    angle closure

    Outcome Measures

    Primary Outcome Measures

    1. Angle closure on gonioscopy [3 weeks]

      The percentage of subjects with angle closure on gonioscopy compared with angle closure on SS-OCT.

    Secondary Outcome Measures

    1. intra-ocular pressure (IOP) [3 weeks]

      The secondary outcome measure is the percentage of patients with presence of an increased intra-ocular pressure (>21 mmHg) during the day or after dark provocation (IOP rise from baseline)

    Other Outcome Measures

    1. Visual field loss [3 weeks]

      The percentage of patients with visual field loss on the HFA visual field.

    2. Retinal nerve fiber layer thickness [3 weeks]

      The mean RNFL thickness will be measured.

    3. Number of corneal endothelial cells [3 weeks]

      The mean number of corneal endothelial cells will be measured

    4. Axial length [3 weeks]

      The mean axial length will be measured.

    5. Anterior chamber angle parameters [3 weeks]

      Parameters analysed from SS-OCT images to determine the morphometric details of the anterior chamber will be measured and means will be calculated. For example AOD500, AOD750, TISA500, TISA750, ARA500, ARA750,TIA500, TIA750, ACD, LV

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    40 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    1. Caucasian race

    2. 40-80 years

    3. Willing and able to comply with scheduled visits and other study procedures

    4. Signed informed consent

    5. Participants derived from the study 'Caucasian patients with angle closure on SS-OCT'

    AND 1 or more of the following:
    • Irido-trabecular contact (ITC) in ≥2 quadrants as seen with SS-OCT in darkened conditions

    • Scleral spur angle (SSA) <20˚ (in 0 and 180º) AND anterior chamber depth (ACD) < 2.5 mm as seen with SS-OCT in darkened conditions

    • The fellow, non-treated eye in a patient after an acute primary angle closure (APAC) attack in the other eye. APAC is defined as an abrupt onset of symptomatic elevation of IOP resulting from total closure of the angle which is typically not self-limiting (although acute attacks can rarely resolve spontaneously).

    Exclusion Criteria:
    1. Any condition including (previous) intraocular laser/incisional surgery or medical procedure or treatment in ophthalmology

    2. Any eye condition/abnormality that will affect the acquisition/reliability of measurement (results), (e.g. vitreous haemorrhage, uveitis, intraocular trauma, significant corneal opacity)

    3. Unable to communicate properly or to understand instructions

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University Eye Clinic Maastricht Maastricht Netherlands 6202AZ

    Sponsors and Collaborators

    • Maastricht University Medical Center

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Maastricht University Medical Center
    ClinicalTrials.gov Identifier:
    NCT02054403
    Other Study ID Numbers:
    • NL47347.068.13/METC 13-2-060
    First Posted:
    Feb 4, 2014
    Last Update Posted:
    Feb 4, 2014
    Last Verified:
    Feb 1, 2014
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 4, 2014